IMNN
Imunon, Inc.Healthcare · $5M market cap
Verdict
We can't put a fair value on IMNN right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow IMNN
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Oct 23, 2026: no open-market purchases and 4 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
Questions about IMNN
Are insiders buying IMNN?
Since Oct 23, 2026: no open-market purchases and 4 other filings (stock awards, tax withholding and similar).
How can I check IMNN's value myself?
Use the free Sticker Price calculator, already filled with IMNN's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About Imunon, Inc.
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Oct 27, 2026. How the Payback Price works